Nurix Therapeutics Announces Scientific Presentations on its BTK Program at the 61st American Society of Hematology Annual Meeting« back

SAN FRANCISCO, November 18, 2019 – Nurix Therapeutics, Inc., a company developing novel therapies that control disease-causing proteins, today announced an oral presentation on its wholly-owned, BTK degrader program for chronic lymphocytic leukemia will be delivered by the Company’s collaborators from the National Institutes of Health at the upcoming 61st American Society of Hematology meeting (ASH). A poster presentation will also be presented on the BTK degradation mechanism of action.  ASH is being held on December 7-10, 2019 at the Orange County Convention Center in Orlando, Fla.

Oral Presentation Details:

Title:                Highly Potent BTK Degradation Induced by NRX0492 As a Therapeutic Strategy for CLL
Session:           605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases I

Hematology Disease Topics & Pathways: Diseases, Leukemia, Biological, Therapies, CLL, immune cells, Lymphoid Malignancies, TKI

Presenter: Deyi Zhang, Laboratory of Lymphoid Malignancies, Hematology Branch, NHLBI, NIH, Bethesda, MD

Date:               Saturday, December 7, 2019 
Time:               1:15 p.m. EST
Location:         W414AB, Level 4

Poster Presentation Details:

Title:                Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies
Session:           605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster III

Hematology Disease Topics & Pathways: Diseases, Leukemia, Biological, Therapies, CLL, immune cells, Lymphoid Malignancies, TKI

Date:               Monday, December 9, 2019  
Time:               6:00 – 8:00 p.m. EST
Location:         Hall B, Level 2

About Nurix Therapeutics

Nurix Therapeutics develops novel therapies that control disease-causing proteins. Nurix’s pipeline is focused on developing drugs as treatments for hematologic cancers and immune-mediated diseases including immuno-oncology therapeutics for cancer. Nurix was founded by internationally recognized experts in E3 ligase biology and immunology and is funded by leading life science investors Third Rock Ventures and The Column Group. The company is headquartered in San Francisco, California. For more information, please visit http://www.nurixtx.com.

Media Contact

Sara Zelkovic
LifeSci Public Relations
Sara@lifescipublicrelations.com